Recommended if funds allow
The advent of human embryonic stem cells (hESCs) has offered enormous potential for regenerative medicine and for basic understanding of human biology. On the one hand, hESCs can be turned into many different cell types in culture dish, and specific cell types derived from hESCs offer an almost infinite source for cellular replacement therapies. This is the primary reason for which hESCs have received much attention from the general public. On the other hand, scientists can study the properties of hESCs and their derivatives, and determine the effect of genes and molecules on such properties either in culture dish or with transplantation studies in live animals. This second aspect of hESC research would not only significantly enhance our understanding of the function of human genes, but will greatly augment our ability to apply hESCs in transplantation therapies and regenerative medicine. To attain the full potential of hESCs, genetic manipulation of hESCs is essential. In this proposal, we will establish the methods to genetically manipulate an increasingly used, non-federally approved hESC line, the HUES-9, and assess the feasibility to use genetically modified HUES-9 cells in cell transplantation studies to assess the integration of hESCs into the mouse central nervous system. We propose to achieve both homologous recombination (i.e. gene targeting) and transgene expression (with bacterial artificial chromosome), which have complementary utilities in assaying gene function in addition to the opportunity to label hESCs or their derivatives with fluorescent markers. Specifically, with genetic engineering of hESCs we will be able to 1) label hESCs and specific cell types derived from hESCs so that they can be readily followed in culture dish and in animals that have received cellular transplants; 2) disturb an endogenous gene or add more copies of a gene so that the effect of a gene of interest can be assessed (for this purpose, a gene involved in the development of a major motor tract, the corticospinal tract, will be studied). We will then transplant genetically engineered hESCs and their derivatives into the embryonic and adult mouse CNS to assess how well these cells integrate into the mouse CNS, and whether such transplanted animals can serve as valid models to study the effect of genes on hESC function in live animals. In transplantation studies involving adult mouse recipients, injured mouse CNS will be used in addition to intact CNS in order to evaluate the potential of hESCs to integrate into injured CNS, which has direct implications on the therapeutic potential of these cells. In summary, our proposal will establish the methods and tools to genetically manipulate HUES-9 cells, explore a paradigm to study human genes and cells in a context of neural development and cellular therapies, and will pave the way for future studies of genes and pathways in basic biology and regenerative medicine with hESCs.
Statement of Benefit to California:
The disability, loss of earning power, and loss of personal freedom associated with spinal cord injury is devastating for the injured individual, and creates a financial burden of an estimated $400,000,000 annually for the state of California. Research is the only solution as currently there are no cures for spinal cord injury. My lab studies the underlying mechanisms for axon regeneration failure after spinal cord injury using mouse genetics and animal models of spinal cord injury. The current proposal aims to genetically manipulate human embryonic stem cells, study their potential to integrate into immature and mature central nervous system and analyze the effect of genes on such integration. Achieving genetic modification of hESCs will expedite studies with hESCs to cure a variety of human diseases and injuries including spinal cord injury. Our studies will pave the way for discoveries that might lead to novel treatment strategies for spinal cord injury and other neurological conditions. Effective treatments promoting functional repair will significantly increase personal independence for people with spinal cord injury, increase earning capacity and financial independence, and thus decrease the financial burden for the State of California. More importantly, treatments that enhance functional recovery will improve the quality of life for those who are directly or indirectly affected by spinal cord injuries.
SYNOPSIS: This proposal is focused on studies to address directed differention of hESC to motor neurons, specifically spinal motor neurons, to address feasibility of using hESC derivatives in CNS development and repair. The focus is on fezl, a zinc finger transcription factor, that has been recently identified in overexpression studies as a master regulator in corticospinal tract (CST) development and cortical spinal motor neuron (CSMN) fate determination in mice. The applicant proposes to: 1) genetically manipulate hESC including making, by homolous recombination, fezl homozygous mutant hESC and also constructing BAC transgene with or without a fezl overexpression cassette; 2)looking at CST development and the role of fezl by transplantation studies of genetically marked hESC into embryonic mice CNS and 3)transplanting genetically modified hESC differentiated into neural precursors into normal and spinal cord injury models to assess potential for integration into mature CNS. SIGNIFICANCE AND INNOVATION: The applicant will apply novel and highly innovative techniques to the study of gene expression in the development and repair of axons in the CNS. Fezl biology likely to be important in understanding biology of corticospinal development and potentially has applicability in repair and/or regeneration in ALS and spinal cord injury. Potential nearer term clinical applicability. STRENGTHS: • Exciting proposal by an extremely well trained, young applicant • Excellent academic environment with top-flight collaborators at UCSD • Has the potential to provide insights leading to clinical application. WEAKNESSES: Potential downside to the fezl knockout/ overexpression strategy is that fezl by itself unlikely to be sufficient (for normal development/regenertion)- ie is not a single gene that acts alone but rather works with other genes. Also the project seems rather ambitious for the two year time span. DISCUSSION: Fez-like is a master gene for development of the corticospinal tract. In KO mice, the whole tract is absent. Overexpression results in an entire extra corticospinal tract. Identification of this master gene now creates an opportunity to study upper motor neurons which are also lost in some forms of neurodegenerative disease. However, no single gene acts alone. So it is a little naive to think that other related genes are not involved in fate switching. In general, the proposal is very exciting and innovative. This is a productive, young investigator who has established a strong collaboration with the Gage laboratory at the Salk nearby. The PI acknowledges the difficulties in homologous recombination and of doing straight transgenesis. PROGRAMMATIC DISCUSSION: During programmatic review, there was an agreement to recommend this applicant for special consideration if funding became available based on: 1) this is a new investigator; 2) scientific merit of proposal 3) applicability of this research to ALS and spinal injury